Key facts
- This page summarizes Argeris N. Karabelas's Form 4 filing for REGENXBIO Inc. (RGNX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Jul 2024, 07:55.
Argeris N. Karabelas - 01 Jul 2024 Form 4 Insider Report for REGENXBIO Inc. (RGNX)
- Reporting relationship
- Director
- Issuer ticker
- RGNX
- Reported as of
- 01 Jul 2024
- Net transaction value
- -$75,091
- SEC form
- 4
- Accepted by SEC
- 03 Jul 2024, 07:55:20 UTC
- Prior SEC filing
- 04 Jun 2024
- Next SEC filing
- 30 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Patrick J. Christmas as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Argeris N. Karabelas filed Form 4 for REGENXBIO Inc. (RGNX) on 03 Jul 2024.
Change
- Previous filing in this sequence was filed on 04 Jun 2024.
- Current net transaction value: -$75,091.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RGNX
transaction
Common Stock
Options Exercise
- Transaction value
- $37,600
- Shares
- +10,000
- Change %
- +89%
- Price
- $3.76*
- Shares after
- 21,286
- Date
- 01 Jul 2024
- Ownership
- Direct
- Footnotes
- F1
RGNX
transaction
Common Stock
Sale
- Transaction value
- $112,691
- Shares
- -10,000
- Change %
- -47%
- Price
- $11.27
- Shares after
- 11,286
- Date
- 01 Jul 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RGNX
transaction
Derivative
Stock Options (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -10,000
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 30,000
- Date
- 01 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $3.76
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
This transaction was effected pursuant to a Rule 10b5-1 trading plan.
Footnote F2
This transaction was executed in multiple trades at prices ranging from $10.98 to $11.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Footnote F3
The previously granted option, representing a right to purchase a total of 40,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2015, and the balance vested in equal monthly installments over the 24 months thereafter.